Ask about this productRelated genes to: BCHE Blocking Peptide
- Gene:
- BCHE NIH gene
- Name:
- butyrylcholinesterase
- Previous symbol:
- CHE1, CHE2
- Synonyms:
- E1
- Chromosome:
- 3q26.1
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2016-10-05
Related products to: BCHE Blocking Peptide
Related articles to: BCHE Blocking Peptide
- Alzheimer's disease (AD) is a disease associated with loss of brain cholinergic functions and a common cause of dementia. Diabetes and inflammation have been linked to some pathways contributing to AD pathogenesis. In this study, the effects of Withania somnifera (W. somnifera) root ethanol extract (WSEE) on lipoxygenase, butyrylcholinesterase (BChE), protein denaturation, and carbohydrate digestive enzymes were determined using in vitro and in silico experimental models. WSEE cytotoxicity on neuroblastoma cell lines (SH-SY5Y) and the molecular docking simulation of its compounds were also investigated. WSEE analysis showed the presence of terpenoids, flavonoids, alkaloids, and tannins. The extract showed significant (p < 0.05) inhibition of protein denaturation (IC = 558.6 µg/mL), lipoxygenase (IC = 175.6 µg/mL) and BChE (IC = 313.6 µg/mL) than ibuprofen (IC = 191.1 µg/mL), vitamin C (IC = 44.97 µg/mL), and rivastigmine (IC = 123.7 µg/mL), respectively. It also inhibited α-glucosidase (IC = 343.0 µg/mL) and reduced SH-SY5Y cell viability at ≥ 80 µg/mL. The docking studies revealed that sitoindoside IX, somniferin, withanolide B, and withasomniferolide B in the plant exhibit high binding affinities, where withasomniferolide B presents the highest docking scores (-11.4 kcal/mol) with α-amylase. Further in vivo and molecular studies are needed to validate the plant's usefulness in AD management. - Source: PubMed
Mulelu LufunoManjia Jacqueline NOlofinsan Kolawole AXulu LondiweMatsabisa Motlalepula G - Medicinal plants remain an important source of therapeutic agents in traditional medicine. Umbilicus horizontalis (Guss.) DC. (U. horizontalis) is traditionally used in Mediterranean folk medicine as a cicatrizing agent for wound healing and for the treatment of inflammatory conditions and pain. However, its phytochemical composition and pharmacological properties remain largely unexplored. - Source: PubMed
Publication date: 2026/06/13
Rayene Dibi AmiraAouachria SanaBenammar LeylaBensouici ChawkiChafaa NassibaZeroual AminaGuemmez ThorayaBaghiani Abderrahmane - The phytochemical profile of several Phoenix dactylifera extracts and evaluation of their antibacterial and anticholinesterase activities were investigated. The extracts were mainly composed of quinic acid, identified as a major constituent in the Ghars variety from Ghardaïa extract (GG), and ferulic acid predominating in the ethanolic extract of Deglat nour seeds (DNS). In addition, major flavonoid glycosides such as rutin, isoquercetin, and hesperidin were detected, with the highest levels observed in DNS. DNS and GG were the most antibacterial extracts, while the other fractions were moderate to weak. The strongest effects matched higher phenolic and flavonoid levels (catechin, quinic acid, isoquercetin), suggesting these compounds drive the activity. Enzyme inhibition assays revealed a selective anticholinesterase potential, with the DNS extract exhibiting dual inhibitory activity against acetylcholinesterase (AChE, IC: 3.17 ± 0.11 µg/mL) and butyrylcholinesterase (BChE, IC: 52.55 ± 0.72 µg/mL). Notably, the AChE inhibitory activity of DNS was stronger than that of the reference standard galantamine (IC: 5.01 ± 0.11 µg/mL), while its BChE inhibition was comparable to the standard (IC: 53.90 ± 0.56 µg/mL). In addition, the Deglat nour spikelet (DNB) extract demonstrated selective BChE inhibition (IC: 43.28 ± 0.83 µg/mL), showing greater potency than galantamine. These findings support the potential use of P. dactylifera as a valuable source of nutraceutical and pharmaceutical compounds. - Source: PubMed
Ferhat MariaKabouche AhmedKabouche ZahiaGazioglu IsilTopçu GülaçtıYilmaz Mustafa AbdullahCakir OguzArica Enes - The deposition of the Aβ peptide extracellularly as diffused and neuritic plaques and intracellular hyperphosphorylated tau (p-tau) protein as neurofibrillary tangles (NFTs) are the key pathological changes observed in the progression of AD. Despite advances in the neuroscience research, the discovery and development of effective therapeutic agents have become challenging task for AD. The molecules modulating multiple targets involved in the disease attracted much attention as promising tools for the effective therapeutic efficacy. Triazole scaffold has been consistently rewarded as a promising versatile lead molecule with a pivotal position in modern medicinal chemistry. It has shown potent inhibitory activity against different targets involved in the progression of the AD including activity against acetylcholinesterase (AChE), butyrylcholinesterase (BChE), amyloid beta (Aβ) accumulation, tau aggregation, neuroinflammation and oxidative stress. Recent reviews label 1,2,3-triazole as first choice scaffold for designing multifunctional hybrid molecules for AD. A comprehensive literature search was performed using PubMed, Scopus, Web of Science, and Google Scholar databases covering publications from 2000 to 2026. This review critically analyzes the evolution of triazole-based therapeutics from single-target cholinesterase inhibitors to modern multitarget-directed ligands. We systematically evaluate how the structural versatility of the 1,2,3- and 1,2,4-triazole cores facilitates interactions with key AD pathological hallmarks. - Source: PubMed
Publication date: 2026/06/09
Malvankar AafreenRaut MaheshSingh Sushil KumarSingh RohitMahindroo NeerajBajad Nilesh - Stanozolol, a synthetic anabolic androgenic steroid (AAS) widely abused to enhance performance, has poorly defined toxicological mechanisms in atherosclerosis (AS). - Source: PubMed
Publication date: 2026/06/06
Li RunwenZhang RuilinLiu JiangTang Yongjiang